Abstract
The biomaterials used in the manufacture of prosthetic devices are vulnerable to microbial colonization. The resulting infections, which form a major proportion of hospital-acquired infections, are refractile to antibiotic therapy and in many cases the device has to be removed before treatment is effective. It is becoming clear that we need more ingenious approaches than simply impregnating biomaterials with antibacterials if we are to develop prostheses that resist infection. In the meantime, there is still enormous scope to reduce the incidence of these infections by ensuring that clinical management complies with best practice.

This publication has 0 references indexed in Scilit: